Download the Monday Daily - American Association for Clinical ...

More documents

Recommendations

Info

2008 AACC AwA r d wi n n e r s Clinical Laboratory Science Leaders Receive Awards At the opening plenary session of the 2008 Annual Meeting, a dozen leaders in the field of clinical laboratory medicine were recognized for their outstanding contributions. AACC President Larry A. Broussard, PhD, DABCC, FACB, and representatives of the sponsoring companies presented the awards. AACC and CLN are proud to note a few of their many accomplishments below. The AACC Lectureship Award Sponsored by an educational grant from Siemens Healthcare Diagnostics P. Roy Vagelos, MD Dr. Vagelos is retired chairman and CEO of Merck & Co. He served as senior surgeon and section head of comparative biochemistry at the National Institutes of Health for a decade. In 1966, he became chair of the department of biological chemistry at the Washington University School of Medicine in St. Louis and in 1973 founded the university’s division of biology and biomedical sciences. He joined Merck in 1975 as senior vice president for research and became president of its research division in 1976. In 1985, he became CEO, a post from which he retired in 1994. Before assuming broader responsibilities of business leadership, Dr. Vagelos had won scientific recognition as an authority on lipids and enzymes and as a research manager. The author of more than 100 scientific papers, he received the Enzyme Chemistry Award of the American Chemical Society in 1976. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He has received 14 honorary doctorates, and his many awards in science and business include the Lawrence A. Wien Prize in Social Responsibility from Columbia University and the National Academy of Sciences Award for Chemistry in Service to Society. He served as chairman of the board of the University of Pennsylvania and chairs the board of visitors at Columbia University Medical Center. He is currently chair of Regeneron Pharmaceuticals and Theravance, two biotech companies. Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine Sponsored by Siemens Healthcare Diagnostics Mary F. Burritt, PhD, FACB, HCLD (ABB) Dr. Burritt is professor of laboratory medicine at the Mayo Clinic College of Medicine and clinical chemist at Mayo Clinic Arizona in Scottsdale. She previously held the positions of medical co-director of the Central Clinical Laboratory and director of the Metals Laboratory at the Mayo Clinic as well as associate dean of the Mayo School of Health Sciences in Rochester, Minn. Dr. Burritt has served AACC in many roles over the past 30 years, including president in 1996 and chair of the annual meeting organizing committee in 2000. Dr. Burritt has been active in the Clinical and Laboratory Standards Insti- 10 CliniCal laboratory news Special edition tute, serving as chair of the Subcommittee on Electrolytes, as chair of the Area Committee on Clinical Chemistry for 5 years, and as a member of the Volunteer Resources/Program Committee. She has also been active on the international level, serving as the vice chair of the Education and Management Division and chair of the visiting lecturer program of the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) for 6 years in each position. Among her contributions in education and research, she directed the postdoctoral training program in clinical chemistry at the Mayo Clinic for 8 years. She has lectured extensively both nationally and internationally on many topics including technical and clinical aspects of ionized calcium, POCT, quality systems, and automation. Dr. Burritt has published more than 195 peer-reviewed articles, abstracts, and chapters. The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics Sponsored by Siemens Healthcare Diagnostics Martin Fleisher, PhD, FACB Dr. Fleisher is chair of the department of clinical laboratories and director of the clinical chemistry laboratory at the Memorial Sloan-Kettering Cancer Center in New York City. Dr. Fleisher joined the medical staff at Memorial Sloan-Kettering as an assistant attending biochemist and spent 35 years working closely with the award’s namesake, Dr. Morton K. Schwartz, then chair of the department of biochemistry. Dr. Fleisher has spent his career in the study, discovery, and development of tumor markers and biomarkers in cancer detection. His interest in biomarkers began in 1970 with the validation of carcinoembryonic antigen in colon cancer. His seminal work on the relationship between breast cancer and cystic mastopathy involved more than 1,000 women, whose breast cyst fluids were analyzed for more than 80 analytes. He investigated the use of biomarkers in node-negative women with breast cancer and developed methods to monitor therapy that are still in use at many medical centers. In collaboration with his neuro-oncology colleagues, he developed cerebrospinal fluid tumor markers. Dr. Fleisher’s current research focuses on the use of biomarkers for new targeted preclinical and clinical drug development and the identification of gene expression patterns in cancer metastasis. An active member of AACC since 1968, Dr. Fleisher has served as national treasurer, a member of the board of directors, co-chair of the 1993 annual meeting, and in many other positions. He is a member of the board of directors of the National Academy of Clinical Biochemistry and president of the Clinical Ligand Assay Society. Award for Outstanding Contributions in Education Sponsored by Quest Diagnostics Nichols Institute William E. Winter, MD, DABCC, FACB Dr. Winter is a professor in the departments of pathology, immunology, and laboratory medicine; pediatrics; and molecular genetics and microbiology at the University of Florida College of Medicine in Gainesville. Dr. Winter directed the pathology residency training program at the University of Florida for 10 years before being appointed as course director for the second year medical student pathology course in 2004. He has given numerous presentations and has published extensively on behalf of AACC. With Dr. M. Signorino, he authored AACC’s monograph, Diabetes Mellitus. With Drs. I. Jialal and D. Chan, he co-authored AACC’s Handbook of Diagnostic Endocrinology. A five-time winner of the AACC Outstanding Speaker Award, Dr. Winter served on the AACC Annual Meeting Organizing Committee in 1998 and 2003 and is presently on the 2009 committee. He chaired the organizing committee for AACC’s professional practice in clinical chemistry course in 2005 and 2007 and chairs the 2009 course. He is a fellow of the National Academy of Clinical Biochemistry and the College of American Pathologists. He is currently a member of the board of directors of the National Academy of Clinical Biochemistry. Including articles, chapters, and abstracts, he has contributed nearly 200 publications that deal with chemistry, coagulation, diabetes, endocrinology, and immunology. Award for Outstanding Contributions In a Selected Area of Research Sponsored by Olympus America Inc., Diagnostic Systems Marilyn A. Huestis, PhD Dr. Huestis is a tenured senior investigator and the chief of the chemistry and drug metabolism section of the clinical pharmacology and therapeutics research branch at the NIDA in Bethesda, Md. She holds an adjunct associate professor appointment at the University of Maryland in Baltimore. She directs a large research program that seeks to discover the mechanisms of action of cannabinoid agonists and antagonists, the effects of in utero drug exposure, and the neurobiology and pharmacokinetics of MDMA (ecstasy). Dr. Huestis currently is the principal investigator of a phase I clinical study evaluating cognitive performance and related brain activation of acute and chronic cannabis exposure using functional magnetic resonance imaging. The study also investigates and contrasts spontaneous and antagonistelicited cannabis withdrawal. Dr. Huestis was director of one of the first forensic urine drug testing laboratories among 150 applicants to be certified by NIDA. She serves on the World Anti-doping Agency’s Prohibited List Committee and the U.S. Anti-Doping Agency’s Research Advisory Panel. Dr. Huestis is past president of the Society of Forensic Toxicologists, past chair of the Toxicology Section of the American Academy of Forensic Sciences, and the first woman president of the International Association of Forensic Toxicologists. She has published 145 peer-reviewed manuscripts, published numerous book chapters and monographs, and presented more than 220 abstracts at national and international meetings. Award for Outstanding Clinical Laboratory Contributions to Improving Patient Safety Sponsored by Ortho Clinical Diagnostics Mario Plebani, MD, FACB Dr. Plebani is full professor of clinical chemistry and clinical molecular biology at the University of Padova School of Medicine, chief of the department of laboratory medicine at the University Hospital of Padova, chief of the Center of Biomedical Research (a specialized center for quality in laboratory medicine for the Veneto Region), and scientific coordinator of the regional anti-doping laboratory at the University Hospital in Padova, Italy. He served as president of the International Society of Enzymology for 5 years and of the Italian Society of Clinical Biochemistry and Molecular Clinical Biology for 4 years. He currently serves on the AACC Patient Safety Advisory Group and the International Advisory Group. Dr. Plebani is reviews editor of Clinical Chemistry and Laboratory Medicine, associate editor of Clinical Biochemistry, CRC Clinical Laboratory Sciences, and International Journal of Biological Markers and editor-in-chief of a journal on clinical governance. His main areas of research are quality in laboratory medicine, biomarkers in cancer and cardiovascular diseases, and in vitro allergy diagnostics. He has published 560 original papers, including a widely cited paper in Clinical Chemistry in 1997 dealing with errors in a stat laboratory that received great acceptance. In 2007 he published a new paper in the same journal describing the laboratory errors situation after 10 years. He is guest editor of a special issue of Clinical Chemistry and Laboratory Medicine dedicated to “Laboratory Medicine and Patient Safety” and author of many papers on the topic of laboratory errors and patient safety. AACC Awards, continued on page 12
AACC Awards, from page 10 Award for Outstanding Contributions Through Service to the Profession Sponsored by Beckman Coulter, Inc. Susan A. Evans, PhD, FACB Dr. Evans is vice president and general manager of Agencourt Bioscience, a Beckman Coulter Company in Beverly, Mass., that provides genomic services and nucleic acid purification products for clinical and life science researchers. She has more than 25 years of experience in the diagnostic industry, holding leadership positions in research and development and now general management. She has developed assays for analytes in the areas of endocrinology, fertility, cardiac markers, and TDM. Dr. Evans’s involvement with AACC began in the 1980s, when she served as an officer in the Florida Section and continued with local section activities in San Diego and Chicago. Her service to AACC on the national level includes being elected to the board of directors, as national secretary, and as president in 2003. She chaired the Program Coordinating Commission twice, was one of the founding members of the Industry Division, and is vice chair of the 2008 Annual Meeting Organizing Committee. She currently serves as president of the National Academy of Clinical Biochemistry, where she has also served on the board of directors. Dr. Evans has also volunteered her time to the IFCC, including as secretary and corporate representative to its Education and Management Division, and to the Clinical Laboratory Standards Institute through membership on several committees. Award for Outstanding Scientific Achievements by a Young Investigator Sponsored by Roche Diagnostics Alex J. Rai, PhD, DABCC, FACB Dr. Rai is an assistant attending clinical chemist in the clinical chemistry service of the department of pathology at Memorial Sloan-Kettering Can- 12 CliniCal laboratory news Special edition cer Center in New York City. During his fellowship training at the Johns Hopkins University School of Medicine, Dr. Rai focused on proteomics- and bioinformatics-based biomarker discovery in ovarian cancer, in addition to his clinical service training. His current research interests lie in the discovery of novel biomarkers for cancer and their translation into clinically useful diagnostic tests. Recent projects have included biomarker discovery using multiplexed gene expression profiling and proteomics techniques, and development of assays for multiplexed single nucleotide polymorphism analysis. He is interested in designing, evaluating, and validating tests for stratifying cancer subtypes and identifying patients unable to metabolize chemotherapeutic drugs. By stratifying a patient’s disease based on biomarker profiles and screening patient genotypes prior to their starting therapy, treatment of a patient’s cancer and selection of the most appropriate therapeutic regimen can be tailored. Dr. Rai has published more than 20 scientific articles and presented more than 25 invited lectures nationally and internationally. He serves on committees for several professional organizations, including the New York Metro Section of AACC, the National Academy of Clinical Biochemistry, and the Clinical Ligand Assay Society. International Travel Fellowship Sponsored by BD Diagnostics— Preanalytical Systems Renze Bais, PhD Dr. Bais is chief operating officer of Pacific Laboratory Medicine Services and clinical senior lecturer in the department of medicine at the University of Sydney. He is also an associate of the Royal College of Pathologists of Australasia. He has been involved in research and development in a variety of areas and published more than 90 scientific papers and book chapters and over 100 abstracts of presentations at both national and international meetings. He recently co-authored two chapters on enzymology for the Tietz Textbook of Clinical Chemistry and for Fundamentals of Clinical Chemistry. He has been active with the IFCC for many years, Genzyme Student Oral Presentations and Poster Contest Monday, July 28 2:00 p.m.–4:30 p.m. Renaissance Washington, D.C. Hotel Congressional Hall B and C This symposium, which highlights research by students, offers presentations of student abstracts in both oral and poster formats. The first hour consists of oral presentations from the four students who received the highest scores in the preliminary judging phase of the contest, and the remainder of the afternoon consists of students competing in the poster contest. Students will compete for cash awards as they are judged on scientific content, originality, and presentation style. These events provide an inspiring glimpse of the future leaders in laboratory medicine. This program is funded by a generous gift provided by Genzyme Corporation to the Van Slyke Foundation. including 6 years as a member of Scientific Division Executive committee and 5 years as a member of the executive board and federation secretary. Dr. Bais has held various positions within the Australasian Association of Clinical Biochemists, including chair of both the South Australian and New South Wales Branches, vice president, and chair of the Scientific and Regulatory Affairs Committee. For the past 5 years, Dr. Bais has been the Australian coordinator of the Australasian Association of Clinical Biochemists/Vietnamese Association of Clinical Biochemistry joint project on quality assurance. This project aims to develop quality systems for Vietnamese laboratories and to set up quality assurance programs in Vietnam. He plans to use this International Travel Fellowship award to further the development of quality systems and assurance programs in Southeast Asian countries. The Edwin F. Ullman Award Sponsored by Siemens Healthcare Diagnostics John F. Burd, PhD Dr. Burd is a co-founder and general partner of Sabur Technology in San Diego, Calif., a company dedicated to developing unique medical testing products. Previously, he was founder and CEO of Oculir, Inc., which developed a remarkable new non-invasive analyte testing technology. Dr. Burd has been a leader in a large number of companies involved in developing medical devices. He was a general partner of Windamere Venture Partners, a firm that started more than 15 medical product and biotechnology companies during his tenure. He was CEO of Mira- Medica, a company developing computeraided detection technology for enhanced cancer diagnosis that was sold to Kodak in August 2003. As president and CEO of Dex- Com, he directed the company’s work to develop, manufacture, and market the first long-term implantable glucose sensor. He was the founder of LXN Corp., which developed the Duet Diabetes Control System and the In Charge Diabetes Control System. LXN was sold to Johnson and Johnson in 2000. At Quidel Corp., he directed the development of enzyme immunoassay products for the clinical laboratory, physician’s office, and home markets. As executive vice president of Mast Immunosystems, his responsibilities included research and development, marketing, sales, and finance. Dr. Burd began his career developing fluorescent immunoassays and performing medical product research and development at Miles Laboratories. Dr. Burd has authored and co-authored numerous articles and his work has led to 25 patents and the development of many innovative products. The AACC Past President’s Award Gary L. Myers, PhD, FACB Dr. Myers is chief of the clinical chemistry branch at the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. He also serves as the scientific director of the World Health Organization Collaborating Center for Reference and Research in Blood Lipids at the CDC. His 30-year career at the CDC has focused on improving the laboratory measurement of biochemical markers used to assess chronic disease risk, particularly cardiovascular disease. Dr. Myers has served AACC at all levels, including chair of the Lipids and Lipoproteins Division, 2002 Annual Meeting Organizing Committee, and 2006 Beckman Conference. He has served on the Meetings Management Group, Nominating Committee, and Board of Directors. Under his leadership, 2007 was an exciting and busy year for AACC as it made progress in all of its strategic initiatives. It was also a transitional year, as Dr. Myers directed the search for a new editor-in-chief for AACC’s flagship journal, Clinical Chemistry. It was a special year for the Web site Lab Tests Online, which expanded into six new countries, including Australia, Germany, Hungary, Italy, Poland, and Spain. Lab Tests Online is recognized as the premier online source for information about laboratory testing. The Personalized Medicine Advisory Group was formed to recommend how AACC should embrace and become active in this rapidly expanding area. Another important initiative was partnering with the Association for Molecular Pathology to develop and offer a molecular pathology review course in 2008. Award for Outstanding Contribution For a Publication in the International Journal Clinical Chemistry Sponsored by Siemens Healthcare Diagnostics Hassan Dihazi, PhD Dr. Dihazi is associate professor, group leader of proteomics in the department of nephrology and rheumatology, and director of the clinical proteomics facility at the Georg-August University in Göttingen, Germany. His research focuses on key proteins connecting cellular stress response pathways to renal diseases. His group also seeks to develop new clinical proteomics approaches for earlier diagnosis of human diseases and biomarker discovery. Dr. Dihazi is a council member of the Human Kidney and Urine Proteomics Project and the European Kidney and Urine Proteomics Association. He is also the co-founder of the Göttingen Proteomics Forum. He is involved in several proteomics journals as an editorial board member and is editor-in-chief of Proteomics Insights. He has published a number of articles on proteomics, especially their relation to kidney function. In his winning article, “Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as differentially excreted protein in diabetic nephropathy patients,” Dr. Dihazi described a robust procedure for the identification and characterization of proteins differentially excreted in the urine of diabetic patients with microalbuminuria and/or macroalbuminuria. He also identified indicators of tissue injury in urine that may result in clinical applications for early diagnosis of diabetes mellitus-related nephropathy. The paper’s co-authors were Gerhard A. Mueller, Sandra Lindner, Markus Meyer, Abdul R. Asif, Michael Oellerich, and Frank Strutz (Clin Chem 2007; 53:9, 1636–1645).
Page 1 and 2: president ’s Welcome PreParing fo
Page 3 and 4: INDUSTRY WORKSHOPS Tuesday, july 29
Page 5: The American Association for Clinic
Page 9 and 10: Divisions Recognize Contributions t
Page 11 and 12: CliniCal laboratory news Special ed
Page 13: industry Workshops, continued from

Download the Monday Daily - American Association for Clinical ...

Create successful ePaper yourself

Delete template?

Save as template?